NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

NOVN.CH

105.76

+1.19%↑

LONN.CH

549.8

+1.03%↑

SDZ.CH

46.56

+2.74%↑

STMN.CH

88.76

+1.23%↑

BANB.CH

59

+1.29%↑

Search

Roche Holding AG

Atidarymo kaina

SektoriusSveikatos priežiūra

302.4 0.87

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

297.2

Max

303.2

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.7B

3.7B

Pardavimai

-15B

16B

P/E

Sektoriaus vid.

22.865

35.739

Dividendų pajamingumas

3.62

Pelno marža

23.266

Darbuotojai

103,249

EBITDA

547M

6.5B

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.62%

3.08%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-368M

205B

Ankstesnė atidarymo kaina

301.53

Ankstesnė uždarymo kaina

302.4

Naujienos nuotaikos

By Acuity

50%

50%

149 / 371 reitingas Healthcare

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-01 08:54; UTC

Pagrindinės rinkos jėgos

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

2025-09-18 14:01; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- 2nd Update

2025-09-18 10:05; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

89bio Shares Soar Premarket on Takeover by Roche

2025-09-18 10:04; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion -- Update

2025-09-18 05:37; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy 89bio for Up to $3.5 Billion

2025-07-24 15:09; UTC

Uždarbis

Roche Weighs Selling Drugs Directly to Patients in Bid to Lower U.S. Prices -- Update

2025-07-24 05:36; UTC

Uždarbis

Roche Backs 2025 Views After Strong Sales of Key Drugs

2025-10-01 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

2025-10-01 09:05; UTC

Karštos akcijos

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

2025-09-18 14:12; UTC

Įsigijimai, susijungimai, perėmimai

89bio Stock Soars 86%. Why Roche Is Buying the Biopharma Company for $3.5 Billion. -- Barrons.com

2025-09-18 07:37; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Roche's 89bio Acquisition Gives Its Drug Pipeline Potential Blockbuster -- Market Talk

2025-09-18 05:09; UTC

Įsigijimai, susijungimai, perėmimai

89bio Says Deal Reflects Potential of Pegozafermin Drug Candidate

2025-09-18 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Deal Is Expected to Close in 4Q

2025-09-18 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Deal Enhanc Portfolio in Cardiovascular, Renal, Metabolic Diseases

2025-09-18 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Roche: MASH Is One of Most Prevalent Comorbidities of Obesity

2025-09-18 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Roche: 89bio Developing Potential Treatment for Metabolic Dysfunction-Associated Steatohepatitis

2025-09-18 05:04; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy 89bio for $14.50 a Share in Cash, Contingent Value Right of Up to $6 a Share

2025-09-18 05:03; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Total Deal Value Is Up to $3.5B

2025-09-18 05:02; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy 89bio

2025-09-18 05:02; UTC

Įsigijimai, susijungimai, perėmimai

Roche Enters Into Deal to Buy 89bio

2025-08-08 10:51; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

2025-08-08 07:39; UTC

Rinkos pokalbiai
Uždarbis

Roche Could Reach Peak Earnings Growth This Year -- Market Talk

2025-08-05 10:40; UTC

Rinkos pokalbiai

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

2025-07-24 06:52; UTC

Rinkos pokalbiai
Uždarbis

Roche Looks Confident in a Tricky Environment -- Market Talk

2025-07-24 05:05; UTC

Uždarbis

Roche Backs 2025 View

2025-07-24 05:05; UTC

Uždarbis

Correct: Roche 1H Diagnostics Sales Down 3%, Reported

2025-07-24 05:04; UTC

Uždarbis

Correct: Roche 1H Sales Rose 4% On Year , Reported

2025-07-24 05:04; UTC

Uždarbis

Roche 1H Net Pft Was Seen at CHF8.4B

2025-07-24 05:04; UTC

Uždarbis

Roche 1H Net Pft CHF7.8B

2025-07-24 05:03; UTC

Uždarbis

Roche 1H Oper Pft CHF12.0B

Akcijų palyginimas

Kainos pokytis

Roche Holding AG Prognozė

Rinkos nuotaikos

By Acuity

149 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
help-icon Live chat